30 Day Trial

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

1Q13 Revenue: Tornier

$82.7MM, +11%* (OrthoHelix $8.4MM) (U.S. $47.9MM, +21%, ex-U.S. $34.6MM, -1%)

  • Total Extremities $67.3MM, +16%* (Upper $48.1MM, +2%, Lower $15.0MM, +115% and 11% pro forma)
  • Sports Med/Biologics $4.1MM, -1%
  • Large Joints/Other $15.3MM, -6%

*Includes acquisition. Pro forma, constant currency growth overall +2%, extremities +4%.

  • Growth led by shoulder arthroplasty products, OrthoHelix IFS Hammer Toe line, Salto Talaris ankle, BioFiber products
  • Commenced full U.S. release of BioFiber CM collagen-coated patch; will start limited user release of high-strength resorbable suture later in year
  • Full commercial launch of Ascend Flex slated for early 3Q; 28 surgeons trained in limited launch
  • 2H13 launches include cementless knee
  • Expecting FDA clearance for Simpliciti shoulder in 1H15
  • Received CE Mark approval for 1st group of OrthoHelix products; planning launch in 3Q to France and Germany